Bradeion Institute of Medical Sciences

Bradeion Institute of Medical Sciences is a specialized research and development entity focused on pioneering next-generation cancer immunotherapies. Founded by the prominent Johns Hopkins research team of Bert Vogelstein, Kenneth Kinzler, and Nickolas Papadopoulos, the organization centers its efforts on Mutation-Associated NeoAntigens (MANAs). The core of their innovation is the MANAbody platform, which generates highly specific TCR-mimic antibodies designed to recognize intracellular mutation fragments presented by MHC molecules. These bispecific antibodies are engineered to target the most prevalent cancer-driving mutations, including those in the TP53 and KRAS genes, which were previously considered undruggable by conventional antibody approaches. By bridging the gap between genomics and immunotherapy, Bradeion aims to develop potent, off-the-shelf treatments for a broad spectrum of solid tumors.